A. Authier-Hall

Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins

J. Berzofsky, A. Heiser, I. Hermans, 2017, Scientific Reports.

Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonist.

D. Zajonc, M. Brimble, D. Godfrey, 2019, Organic & biomolecular chemistry.

Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy

B. Delahunt, I. Hermans, G. Painter, 2021, Frontiers in Immunology.

NKT cell-dependent glycolipid–peptide vaccines with potent anti-tumour activity† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c4sc03599b Click here for additional data file. Click here for additional data file.

M. Brimble, I. Hermans, O. Gasser, 2015, Chemical science.

Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants

A. Sher, K. Subbarao, E. Parker, 2023, iScience.

A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma

Rajiv Kumar, M. Brimble, V. Hinder, 2023, Cancer Immunology, Immunotherapy.

Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins

J. Berzofsky, A. Heiser, I. Hermans, 2017, Scientific Reports.